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3Other Targetable Sarcomas
Veridiana Pires de Camargo,a,1 Matt van de Rijn,b,1 Enrique de Alava,c,1 Juan Madoz-Gúrpide,c,1
Silvana Pilotti,d,1 Margaret von Mehren,e,1 Florence Pedeutour,f,1 Robert G. Maki,a,1
Piotr Rutkowski,g,2 and David M. Thomash,2
Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and
reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent
potential targets for systemic therapy. In addition, there are cancer cell survival pathways that may
not be the target of chromosomal translocations or mutations that are still estimable targets for new
systemic therapeutics, be it pathways involved in angiogenesis or apoptosis. In this review, we
examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new
techniques being used to delineate novel therapeutic inroads for patients with sarcoma.
Semin Oncol 36:358-371 © 2009 Elsevier Inc. All rights reserved.a
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bELECTING A TREATMENT TARGET
N SARCOMA
ne of the primary tenets of oncology is to
determine whether treatment is going to be
curative or palliative in intent. This basic dis-
inction has marked ramifications regarding the desir-
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Semi58bility of local and systemic therapeutic options alike.
hile surgery, radiation, and standard cytotoxic che-
otherapy are frequently employed in both primary
nd metastatic therapy for patients with sarcomas,
hese modalities are neither tumor-specific nor tumor
ubtype-specific. Particularly for cytotoxic chemother-
py, there is typically limited benefit, except in the case
f adjuvant therapy of pediatric sarcomas, in which
ase chemotherapy is mandatory given its high rate of
fficacy in primary disease.
Is it possible to think about metastatic disease as
ltimately curable? As ever is the case for sarcomas,
astrointestinal stromal tumor (GIST) provides a para-
igm. Prior to 2000, recurrent GIST was uniformly
atal, given the overall resistance of GIST to standard
ytotoxic chemotherapy. While biological factors such
s elevated multidrug resistance proteins may explain
ome of this effect, there are likely other factors that
e still do not understand as the principal reasons for
vert chemotherapy resistance of GIST.
The identification of mutations in KIT in GIST1 com-
letely transformed the therapy of GIST with imatinib
nd other tyrosine kinase inhibitors commercially ap-
roved or under study at present. We also understand
hat there are variations in the risk of recurrence of
IST based on mitotic rate, size, and anatomical loca-
ion of the primary tumor. These findings are under-
cored by the finding of unique gene expression array
atterns of GIST based on anatomical location, which
ave begun to have an impact on patient care with the
nding in one study of the importance of higher dose
matinib in improving progression-free survival (PFS)
n this agent. However, overall survival is no different
ased on dose, probably due to effects of crossing over
f patients from lower to higher dose imatinib.
nars in Oncology, Vol 36, No 4, August 2009, pp 358-371
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Other targetable sarcomas 359Thus, GIST has taught us important lessons on how
o match a specific drug to a specific sarcoma (or other
ancer) subtype (Table 1). Is the presence of a target
ufficient? Clearly not. In the setting of small cell lung
ancer and seminoma, there is abundant KIT expres-
ion, yet the response rate to imatinib in these diseases
s essentially zero. For an example with sarcomas, in
he case of malignant peripheral nerve sheath tumor
nd synovial sarcoma, there is both expression and
mplification of HER1/EGFR; however, clinical trials of
pidermal growth factor receptor (EGFR)-targeted ther-
py yielded a median PFS of 2 months, ie, one scanning
nterval.
The striking results with trabectedin (ET-743) in
yxoid/round cell liposarcoma (M/RCLS)2 also high-
ight the use of a novel agent in a specific sarcoma
ubtype. Trabectedin is both a minor groove alkylator,
ike mitomycin, but also interferes with transcription-
oupled nucleotide excision repair and inhibits the
ranscription of heat shock–inducible genes, causing
NA strand breaks, late S/G2 cell cycle arrest, and
53-independent apoptosis. M/RCLS, the second most
ommon class of liposarcomas, are particularly sensi-
ive to trabectedin for unclear reasons. Despite its well
ecognized t(12; 16) involving genes FUS-CHOP, FUS-
HOP fusion gene expression did not change in quan-
ity before and after therapy, leaving some question as
o mechanisms of action for a given patient’s tumor.2
ther factors may be involved in this pattern of sensi-
ivity, as borne out by the BRCA1/ERCC1 fingerprint of
arcomas found to be sensitive and insensitive to tra-
ectedin.3
How do we know when a target is relevant? Through
n understanding of tumor pathophysiology, understand-
ng what and how the drug blocks the target, and
dentification of the ideal patient population for each
reatment. While for GIST this was relatively straight
orward, it is much less clear for other targeted agents,
iven the lower frequency of specific mutations in
ritical genes identified in other sarcomas to date.
Table 1. Lessons on Selecting a Drug to Test
Against Sarcoma (or other cancer)
1. The target must be biologically relevant, eg,
KIT and PDGFR in GIST
2. Treatment need not be cytotoxic for benefit,
though such benefit becomes more difficult
to evaluate in at least some situations
3. Therapy must have limited toxicity due to
the need for chronic administration
4. Over time, cancer cells evolve mechanisms
to bypass the inhibited targethere are ongoing efforts from bench to translational pesearcher to bedside, to synthesize data from genomic
nd proteomic studies, to evaluate the biological impli-
ations of findings, to determine how possible it is to
lock a target, and to develop the strategies to test new
gent most effectively, not to mention trying to identify
merging resistance mechanisms.
Given the present state of available agents and what
as been seen to date with single agents, it is clear the
ure rate for patients with metastatic disease will prob-
bly only increase with the use of combinations of
argeted therapeutics (and perhaps also with standard
ytotoxic drugs). If we cannot achieve cure for the
ime being, hopefully it is possible for other sarcomas,
ike GIST, to make them truly chronic diseases and not
mmediately life-threatening ones.
ENE PROFILING TO FIND TARGETS
We have been the middle of an explosion of infor-
ation regarding patterns of gene and protein expres-
ion of sarcomas. It is clear that even small amounts of
ata regarding specific mRNA expression markers in
pecific sarcoma subtypes can be rapidly confirmed on
arger scale tissue microarrays using immunohisto-
hemistry and in situ hybridization. These types of
tudies have led to identification of markers such as
OG1 for GIST,4–6 TLE1 in synovial sarcoma,7 S100P in
ladder carcinoma,8–10 and CK17 in breast adenocarci-
oma.11 With the development of new diagnostic and
rognostic markers, we can recognize subsets of cases
ithin a diagnostic entity, and thus more accurately
arget novel therapeutics as they become available.
We see from the examples of GIST (KIT and PDGFR-
lpha) that high expression of a tyrosine kinase recep-
or (TKR) is associated with a mutation in the protein
tself, or sometimes a translocation involving the ligand
or that receptor, eg, PDGFR-beta in dermatofibrosar-
oma protuberans (DFSP).
Matt van de Rijn and colleagues hypothesized that
creening for high expression of TKRs on a tissue
icroarray would identify novel targets for sarcoma
herapeutics. In this way CSF1 ligand was identified in
small portion of cells in tenosynovial giant cell tumor
TGCT) and pigmented villonodular synovitis (PVNS),
hile nearly all cells in the tumor are positive for the
eceptor, CSF1R.12 A translocation was demonstrated
nvolving chromosomes 1 and 2 using breakaway fluo-
escence in situ hybridization (FISH) probes, but the
nvestigators found this translocation only in a minority
f the tumor cells, indicating that the tumor cells ex-
ressed CSF1 and recruited inflammatory cells such as
onocytes into the lesion, consistent with the inflam-
atory appearance of such lesions. Like DFSP, this
eads to an autocrine loop as well, which drives tumor
roliferation and survival. Remarkably, a recent case
eport indicates that imatinib, which blocks not only
latelet-derived growth factor (PDGF) receptors, KIT,
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360 V. Pires de Camargo et alnd BCR-ABL but also CSF1R, can lead to clinical re-
ponses in patients with TGCT/PVNS.13
These data have now been used to model a different
ype of cancer and its outcome. High plasma levels of
SF1 expression are associated with breast cancer
isk.14 Furthermore, in animal models a decrease in
umor-associated macrophages through decreasing
SF1 levels inhibits tumor progression.15 It was thus
ypothesized that expression profiling of TGCT/PVNS
ould define a CSF1-based gene expression profile. A
60-gene pattern typical of TGCT/PVNS was defined,
nd then used to cluster 295 breast carcinomas by this
attern. This gave two clusters of tumors, some with
he TGCT/PVNS CSF1 gene signature, and others with-
ut. This gene set was filtered through five different
reast cancer datasets to further narrow the key genes
f the CSF1 gene signature, and showed that this gene
et is associated with a higher grade of tumor and
egative estrogen receptor expression.16–18
This gene profile also has been applied to leiomyo-
arcoma (LMS). We knew that CD163/CD68 histiocyte
umbers correlated with poor outcome in extrauterine
but not uterine) LMS19. Both uterine and nonuterine
MS could be clustered with this basis set of CSF1-
elated genes, and those people with a CSF1 expression
attern in their LMS fared worse than those without the
SF1 expression pattern.19 Since CSF1 could be shown
o be produced by at least some LMS cells, CSF1 and its
ownstream targets thus become a target for therapy
or LMS, which will have to be evaluated prospectively
n trials of imatinib in patients with tumors with this
xpression pattern.
HE ROLE OF PROTEOMICS
N THE SEARCH FOR NEW
HERAPEUTIC TARGETS IN SARCOMAS
elevance of Proteomics in the
iscovery of New Therapeutic Targets in Sarcomas
Frequently, many relevant discoveries in biomedical
ciences have their origins in the investigation of dif-
erences between one functional state of a biological
ystem versus another. Differences between cellular
tates are reflected in changes in gene expression that
anifest themselves at the level of both the messenger
mRNA) and the final product (protein). Proteins are
lmost always the effectors of biological functions, but
rotein levels depend not only on the levels of the
orresponding messages but also on a multitude of
ranslational controls, post-translational modifications,
nd regulated degradation.20,21 The expression levels of
ll proteins would arguably provide the most relevant
ingle data set characterizing a biological system.
A number of decisive breakthroughs in proteomics
ave materialized, including protocols to handle small
mounts of biological samples, the ability to rapidly Edentify peptides, and the direct analysis of very com-
lex protein mixtures.22,23 Over the last two decades,
wo-dimensional electrophoresis (2-DE) has established
tself as the de facto approach to separating proteins
rom cell and tissue samples. More recently, mass spec-
rometry (MS) also has become a powerful tool for
etecting posttranslational modifications and protein
nteractions. Even now, progress on quantitative meth-
ds has allowed the determination of quantitative sys-
ems-wide measurement of protein expression levels.24
owadays, the conceptual strategies and technological
chievements of “proteomics,” which aims to provide
ust that, have proven ready to tackle comprehensive
rotein expression analysis, even at a systems-wide
evel.25 The combination of complementary proteom-
cs tools, such as 2-DE, matrix-assisted laser desorption/
onization-time of flight mass spectrometry (MALDI-ToF
S), and bioinformatics offer to the biomedical re-
earcher an opportunity to study the profile of changes
n protein levels.
In many cases, sarcoma cell lines are employed
s model systems wherein mechanistic molecular
chemes are studied. Control of cell-cycle progression,
ediation of invasion and migration, evasion of apo-
tosis, etc constitute checkpoints that are usually in-
estigated in cell line models of different types of tu-
ors in response to different agents. Using different
odels of sarcoma xenografts (SK-N-MC and IMR32
neuroblastoma], RH1 and RH30 [rhabdomyosarcoma],
nd KHOS/NP [osteosarcoma]), Izbicka et al evaluated
nd compared the effects of docetaxel and paclitaxel.26
he approach used immunoblotting and surface-en-
anced laser desorption/ionization (SELDI) MS to as-
ess drug effects on the expression of the beta-tubulin
sotypes and apoptotic markers (Bcl-2, Bax, Bcl-XL).
owever, the results of this anticancer activity showed
o apparent correlation with drug effects on those
roteins. The drugs had significantly different, yet
ighly heterogeneous effects on the tumor levels of the
roteins. In contrast, six protein species identified by
roteomic profiling were consistently and differentially
egulated by docetaxel and paclitaxel in all xeno-
rafts.26
The study of Ewing sarcoma also has provided exam-
les of how proteomics may deepen our understanding
bout the mechanisms regulating the response to differ-
nt treatments. Ewing sarcoma expresses several deregu-
ated autocrine loops mediating cell survival and prolif-
ration that contribute to its pathogenesis. Insulin-like
rowth factor 1 receptor (IGF1R) and KIT are trans-
embrane receptors that mediate two of these
oops,27,28 and are therefore directly involved in the
rowth and survival properties of Ewing sarcoma.29–31
heir blockade, therefore, is a promising therapeutic
pproach for this neoplasm. Martins et al reported the
n vitro impact of IGF1R/KIT pathway blockade on
wing sarcoma cell lines,32 and they have extended
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Other targetable sarcomas 361heir observations to the level of proteomic changes
nduced by this treatment, to find and validate new
ossible therapeutic targets.33 Two-dimensional gel
lectrophoretic analysis and MALDI-ToF studies of Ew-
ng sarcoma cell lines treated with ADW742 and/or
matinib (specific IGF1R/KIT inhibitors) revealed a
arge panel of differentially expressed proteins, some of
hem related to stress-induced response. Among them,
he changes in protein expression between cell lines
ensitive and resistant to IGF1R/KIT inhibitors were
articularly significant in the case of heat shock protein
0 (HSP90).33
Response to stress is a key mechanism conditioning
rug sensitivity. Stress-protective HSPs are often over-
xpressed in neoplastic tissues and cancer cell lines,
nd therefore HSP inhibition might become a new
herapeutic strategy to inhibit multiple receptor path-
ays. The authors illustrated that inhibition of HSP90
ith 17-AAG (a specific HSP90 inhibitor) and siRNA
gainst HSP90 reduced Ewing sarcoma cell line growth
nd survival, especially in cell lines that previously
howed resistance to IGF1R/KIT pathway blockade.33
7-AAG treatment induced HSP90 client protein degra-
ation, including AKT, KIT, or IGF1R, by inhibiting
heir physical interaction with HSP90. Animal models
onfirmed that HSP90 inhibition, alone or combined
ith IGF1R inhibition, significantly reduced tumor
rowth and expression of client proteins. The authors
ostulate, for the first time in Ewing sarcoma, that in
ddition to the levels of expression and basal activation
f IGF1R/KIT, the development level of the stress re-
ponse mechanism is another important determinant of
ensitivity to IGF1R inhibitors or KIT inhibitors in Ew-
ng sarcoma cell lines. Importantly, targeting HSP90
unction might be of therapeutic value in Ewing sar-
oma, especially in cases of previous resistance to KIT
r IGF1R pathway blockade.
hallenges and Near-Term
erspectives for Proteomics in Sarcoma Research
We are convinced that, along with cellular, molec-
lar, and genomic advances, novel proteomic ap-
roaches may be more efficient and allow monitoring
f changes in protein expression, modification, and
ifferentiation patterns associated with fusion protein
xpression in sarcomas. It also has been suggested that
et unidentified genetic factors cooperate with the
himeric transcription factors to induce oncogenesis.
roteomics also should allow the delineation of the
ownstream pathway(s) unleashed by the aberrant mal-
unction of sarcoma chimeric proteins. All of the genes
nd proteins involved in a game of consecutive, orches-
rated, anomalous interactions should be unraveled, so
he effectors of endpoints of chimera expression in
ifferent cellular contexts could be targeted. Even
ore subtle qualitative and quantitative differences in dxpression patterns are associated with different sar-
oma fusion types that result from variability in
enomic breakpoint locations. Bearing in mind that the
ajority of molecular effectors in cellular processes are
roteins, and that most new anti-cancer agents cur-
ently available are addressed against protein targets,
e believe that a proteomic perspective, complemen-
ary to that of genomic biology, would bring extended
hoices to render new therapies in sarcoma treatment.
Sarcoma chimeric proteins with DNA binding do-
ains may induce tumorigenesis by perturbing gene
xpression. At the same time, they also interact with
ther proteins involved in different aspects of mRNA
nd DNA metabolism, suggesting novel physiological
oles in the global process of tumor formation. A com-
rehensive characterization of the molecular structure
f the fusion protein would provide greater detail of
he mechanisms underlying the functional activities of
he chimeras. In return, all of this knowledge will
rovide clues to allow us to develop sarcoma protein-
pecific inhibitors with therapeutic potential. Given
he unique specific interactions of every sarcoma pro-
ein with other cellular proteins34 and the absolute
umor specificity of fusion proteins, this possibility may
ell come to pass in the near future.
Finally, we also must be cognizant of the potential of
esearch in posttranslational protein modifications
PTMs). PTMs are covalent processing events that
hange the properties of a protein by proteolytic cleav-
ge or by addition of a modifying group to one or more
mino acids. They may alter physical and chemical
roperties, folding, conformation distribution, stability,
ctivity, and, consequently, function of the proteins.
TMs modulate the activity of most eukaryote proteins,
nd can determine its activity state, localization, turn-
ver, and interactions with other proteins. Examples of
he biological effects of protein modifications include
hosphorylation for signal transduction, ubiquitination
or proteolysis, attachment of fatty acids for membrane
nchoring and association, glycosylation for protein
alf-life, targeting, and cell–cell and cell–matrix inter-
ctions. In signaling, for example, kinase cascades are
urned on and off by the reversible addition and removal
f phosphate groups.35 Consequently, the analysis of pro-
eins and their posttranslational modifications is critical
or the study of cancer, andwe envision that this might be
articularly the case for sarcomas, where the function of
he chimera protein determines the cascade of events
ltimately leading to tumorigenesis.
Despite advances in our understanding of the biology
f sarcomas, more remains to be learned about the factors
hat impart varying clinical outcomes in this disease. This
s necessary to further expand therapeutic options and
dentify better prognostic factors that would make a
ifference in patient outcomes.
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362 V. Pires de Camargo et alON-MUTATIONAL RECEPTOR
YROSINE KINASE ALTERATIONS IN SARCOMAS
Sarcomas carrying non-mutational receptor tyrosine
inase (RTK) alterations are a subset of sarcomas that
re addicted through an RTK activation mechanism
represented by an autocrine/paracrine loop or the
ain or loss of a gene or chimeric fusion protein) that
an be targeted by selective drugs. While in general the
resence of target mutations has predicted responses
o molecular therapeutic agents, in some cases the
ctivation of druggable RTK pathways is not associated
ith mutational events. In addition, even where muta-
ions have been defined, the druggable target may rep-
esent a downstream mediator of this RTK pathway,
ather than the mutant itself. These “non-mutational”
lterations are of substantial clinical interest, since
ithin any given cancer, mutations may affect different
lements of multi-component pathways. The most dis-
al, obligate downstream component may be the most
ational target for the tumor class as a whole, regardless
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The challenge is to identify these key RTK pathways.
ver the last few years, a number of reports have
escribed possibly targetable profiles in various several
arcomas,36–47 but fewer than half of these tumors
howed clinical responses.37,41,43,46–48 We will here con-
entrate on two responding sarcomas: chordomas and
lveolar soft part sarcomas (ASPS), and give real exam-
les of detection of activation of kinases in these tu-
ors as a means how this type of research can inform
linical studies of new agents.
hordoma
PDGFR-beta appears to be activated by an autocrine
oop in chordomas; targeting this receptor by means of
selective tyrosine kinase (TK) inhibitor (imatinib)
eads to therapeutic benefits and objective imaging re-
ponses.41,42,48,49 However, the observation of primary re-
istance to imatinib in some patients prompted us to
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Other targetable sarcomas 363eanalyze our cryopreserved case material from the pre-
matinib era for the presence of other activated RTKs.
Using human phospho-RTK antibody arrays, upstream
argets in four randomly selected cases were examined,
nd surprisingly, in addition to the recognized activation
f imatinib-sensitive PDGFR-beta and RTKs of the same
amily (Flt3 andMCSFR1), activation of RTKs belonging to
he EGFR family were observed: mainly EGFR itself
HER1), followed by HER2/neu and, to a lesser extent,
ER4 (Figure 1).
These data were confirmed by biochemical analyses
f the same specimens and, interestingly, comparison
f the biochemical and immunohistochemical data
howed that all but one of the cases tested for EGFR
ere negative for EGFR and Her2/neu protein expres-
ion, whereas comparison of the biochemical and FISH
ata of all of the cases showed that both genes were
eregulated, and with an identical profile, thus suggest-
ng that FISH may be a more useful predictive assay
han immunohistochemistry.
Subsequent analysis of the downstream targets
howed that both the PI3K/AKT and RAS/ERK 1–2 path-
ays were activated in the absence of any mutations of
he genes belonging to them (PI3Kp110 and PTEN, and
AS and BRAF). FISH analysis of PI3K did not reveal
ny numerical alterations, but more than half of the
ases showed PTEN monosomy, which, however,
eemed to have no effect on PTEN function as immu-
igure 2. Western blot for mTOR1 and phospho-mTOR1 (
n most cases. (Courtesy of S. Pilotti.)oprecipitation experiments did not reveal any change
n the amount of protein. Furthermore, in line with
ublished data indicating that mammalian target of
apamycin (mTOR) is stimulated by both the RAS and
I3K pathways,50 we found that the mTOR complex 1
raptor) and its target ribosomal protein S6 were ex-
ressed and activated, although the latter was only
xpressed and activated at a low level and, unexpect-
dly, not at all in two cases (Figure 2). One possible
eason for the lack of S6 expression could be the loss of
he 9p21 locus to which both S6 and p16 map: p16 was
eregulated in 70% of the cases series and was homozy-
ously deleted in the two cases not expressing S6.
These new insights into the TK profile of chordomas
ndicate that, in addition to or instead of PDGFR inhi-
itors, it may be useful to use inhibitors of EGFR,
nhibitors of both EGFR (HER1) and HER2/neu, as well
s inhibitors of mTOR/raptor.
lveolar Soft Part Sarcomas
ASPS are rare tumors that mainly affect young pa-
ients and are clinically characterized by prolonged
urvival combined with a high rate of metastatic dis-
ase and chemo-resistance, and molecularly character-
zed by an ASPLCR1-TFE3 translocation. There is one
ublished report with a case of ASPS with brain metas-
ases successfully treated with angiogenic inhibitors,51
in chordoma patient samples, showing activation of mTORraptor)
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364 V. Pires de Camargo et alnd two more recent papers have provided evidence
hat unregulated TFE3 overexpression in the context of
he ASPLCR1-TFE3 fusion transcript plays a role in the
athobiology of ASPS.52,53
In the light of this finding, and reports of the clinical
ffectiveness of sunitinib (in two patients with disease
egression) in stage IV ASPS patients, the RTK activa-
ion profile of four primary tumors was examined by
nvestigating upstream and downstream targets, and
he possible mechanisms of activation of the upstream
TKs using biochemical analysis of frozen material (us-
ng human phospho-RTK antibody arrays and IP/WB,
nd mutational and reverse transcriptase–polymerase
hain reaction [RT-PCR] expression analyses) and im-
unohistochemistry and FISH analyses of related for-
alin-fixed, paraffin-embedded samples.
The upstream target analysis (RTK array and immu-
oprecipitation/Western blot) indicated an activation
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igure 3. Phosphokinase dot blot for four patients with alv
vident in most cases, with variable expression of other kinrofile involving the PDGFR (PDGFR-beta, Flt3, or M- tSFR), EGFR, and MET families in all four cases, and
EGFR1/VEGFR2 in one (Figures 3 and 4). We there-
ore investigated the downstream PI3K/AKT and RAS/
RK pathways, which showed strong activation (as
reviously reported),53 as well as mTOR and its targets
6K and S6, which were all activated in the absence of
ny deregulation of upstream or downstream effectors
Figure 5). As this suggested the support of upstream RTK
ctivation, we looked for the activation mechanisms by
eans of mutational and FISH analyses together with
T-PCR of the cognate ligands of PDGFR, EGFR, andMET,
he results of which were consistent with the presence of
igand-dependent activation in all cases.
Taken together, these promising preliminary find-
ngs suggest that ASPS are mainly characterized by the
utocrine/paracrine activation of PDGFRs, MET, and, to
lesser extent, VEGFR. The fact that all of these are
argets of sunitinib provides a rationale for its use, but
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Other targetable sarcomas 365erimental data) also suggests that MET inhibitors may
e useful. Furthermore, tumoral “addiction” to EGFR or
ther RTKs has to be ruled out in the case of sunitinib-
esistant tumors. Finally, these types of experiments
ill be very helpful for identifying new targets in other
arcoma subtypes.
ENETICS OF WELL-DIFFERENTIATED/
EDIFFERENTIATED LIPOSARCOMA
DENTIFYING TARGETS FOR THERAPY
Well-differentiated and dedifferentiated liposarco-
as (WD/DDLS) form a spectrum of tumors, and are
he most common of the three forms of liposarcoma,
epresenting about half of liposarcomas. M/RCLS
igure 4. Robust expression of MET in ASPS patient sampl
ome cases. (Courtesy of S. Pilotti.)
igure 5. Activation of S6 kinase by Western blot in ASPS
aatient samples. (Courtesy of S. Pilotti.)characterized by the t(12;16) FUS-CHOP transloca-
ion) and the much less common pleomorphic lipo-
arcoma (with an aneuploid karyotype more like
igh-grade malignant fibrous histiocytoma/high-grade
ifferentiated pleomorphic sarcoma [MFH/HGUPS])
epresent the other half of the liposarcomas observed.
ipomas, which also have some of the similar genetic
lterations as WDLS, are at least 100 times more com-
on as liposarcomas.
WDLS have a relatively simple karyotype that is
argely diploid with supernumerary ring or giant
arker chromosomes. As tumors are observed to be
ess histologically differentiated (DDLS), there is an
ncrease in the complexity of the genotype, with
olyploidy and aneuploidy common, as well as con-
inued development of the ring and marker chromo-
omes, consistent with a spectrum of tumors with
ncreasingly chaotic chromosomal arrangements as
he tumor is found to be less differentiated.
The ring, giant, and marker chromosomes found
n WD/DDLS are observed to contain amplifications
f the chromosomal region 12q14–15 region that
ontains important oncogenes such as MDM2 and
DK4, easily observed by FISH or by array compar-
tive genomic hybridization (CGH)54 (Figure 6). In-
erestingly, in terms of propagation of the aneuploid
aryotype after cell division, ring, satellite, and
arker chromosomes do not contain the character-
stic alpha-satellite sequences of centromeric DNA as
ites of spindle attachment during cell division, and
evidence of phosphorylation (activation) of MET in at leastes, withre termed neocentromeres.
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366 V. Pires de Camargo et alMDM2 is found at 12q15, and CDK4 at 12q14.1. The
mplification of this region helps in distinguishing
DLS from lipomas, and DDLS from other poorly dif-
erentiated malignancies.55–58 Immunohistochemistry
or MDM2 can be somewhat useful in diagnosis, but
here are false positives, false negatives, and difficulties
n interpretation of even technically well-executed im-
unohistochemistry. Molecular detection of MDM2 by
ISH or quantitative polymerase chain reaction (Q-
CR) testing provides a better diagnostic for MDM2
mplification in these tumors. Tumors that are neg-
tive for amplification can be evaluated for the pres-
nce of other markers more characteristic of lipo-
as, M/RCLS, or other diagnoses. Short of wholesale
mplification of chromosome 12q, low-level gains of
DM2 and/or CDK4 are observed in both lipomas
nd atypical lipomatous tumors (the lowest grade
ersion of liposarcoma), perhaps representing the
issing transition state between lipoma and overt
D/DDLS.
MDM2 and CDK4 are not the only genes amplified
n the chromosome 12q amplicon of WD/DDLS. A
arge series of WD/DDLS yielded evidence of variable
mplification of other genes between MDM2 and
DK4, such as HMGA2, YEATS4, and CHOP/
DIT3.59 Perhaps reflecting a somewhat secondary
ole of the gene in comparison to MDM2 in this
iagnosis, CDK4 is not necessarily amplified in all
D/DDLS. Those that do not have CDK4 amplifica-
ion are less often found in a retroperitoneal primary
ocation. Perhaps CDK4 amplification can be re-
laced by other genetic events that provide the same
igure 6. Amplification of MDM2 demonstrated in we
omparative genomic hybridization (CGH) and (right) flu
. Pedeutour.)urvival advantage in these cases. As a result, we pelieve that MDM2 and CDK4 are the cores of two
istinct amplicons on chromosome 12q.
Other genes on chromosome 12q also bear further
omment. Portions of the HMGA2 gene are consis-
ently amplified, rearranged, and overexpressed in
D/DDLS at 12q14.3. In particular, exons 1 and 2
ppear to be the minimal portion of the gene amplified
hen comparing multiple different copies of the gene
rom different tumors. It is also characteristically over-
xpressed in lipomas, as an indicator of the potential
mportance of the gene in the initiation of adipose
umors. YEATS4 (also called GAS41) interferes with
53 function (as does MDM2), and is amplified in
liomas as well as in approximately 80% of WD/DDLS.
he gene DDIT3 (CHOP), the translocation partner for
US in myxoid liposarcomas, is often overexpressed in
D/DDLS independent of any amplification, suggest-
ng the importance of this gene in the generation of
iposarcomas in general.
Strategies to overexpress these genes in cell lines, as
ell as knock-down experiments in existing liposar-
oma lines, will no doubt tell us more about how these
enes function in the future. Clearly, the existence of
harmacological agents that block MDM2 or CDK4
unction point to novel agents worth examining in
D/DDLS. Furthermore, preclinical studies using WD/
DLS cell lines show indications of activity, based on
ata from cell lines and xenografts.60 Hopefully pathol-
gy analyses of liposarcoma patient tissues on such
herapies will help inform us as to the utility of drugs
hat block MDM2 or CDK4 function in patients in the
ear future, since these agents are now available in
ntiated–dedifferentiated liposarcomas by a (left) array
ce in situ hybridization (FISH). (Courtesy of A. Aurias andll-differe
orescenhase I clinical trials.
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Other targetable sarcomas 367ARGETING ANGIOGENESIS IN SARCOMA
Blood vessel formation is the first event in embryo-
enesis that allows for growth, through the develop-
ent of conduits that carry oxygen and nutrients to
eveloping peripheral tissues. Through a balletic inter-
lay of growth factors and blood vessel precursors,
lood vessels are generated during development, typi-
ally termed “vasculogenesis.” The term “angiogenesis”
s generally used for the formation of thin wall endo-
helial structures with or without smooth muscle and
ericytes once initial embryogenesis is complete. An-
iogenesis is also the repair mechanism by which blood
essels grow into normal tissues after injury. Arterio-
enesis, the development of stronger structures cov-
red with a tunica media and adventitia, is a separate
rocess employing different precursor cells.
There are two forms of angiogenesis, specifically
prouting and splitting/intussiceptive angiogenesis,
hich are being modeled with increasing sophistica-
ion.61 The former process involves the use of a gradi-
nt of a vascular growth factor to form a leading “bud”
f a new vessel into tissue. Splitting angiogenesis refers
o the duplication of the cells in the existing (cylindri-
al) wall of the vessel to make it longer or to allow
ormation of new branches. These same processes are
o-opted by a tumor to allow for neoangiogenesis into
umors for their continued growth.
More than 35 years ago, Judah Folkman, who just
ecently passed away, proposed that tumors rely on
ngiogenesis for their continued growth, and that ap-
roaches to block this cascade of events would be
ffective antineoplastic agents.62 This was first demon-
trated clinically in giant hemangiomas in children with
he use of alfa-interferon, although the mechanism re-
ained unclear.63 An explosion of research has identi-
ed a palette of circulating endothelial factors that are
esponsible for different aspects of the angiogenic pro-
ess, including vascular endothelial growth factor
VEGF), fibroblast growth factor 2 (FGF2), transform-
ng growth factor-beta (TGF-), PDGF, angiopoietins 1
nd 2, angiostatin, endostatin, and others. The function
f each of these factors in vasculogenesis, angiogene-
is, or arteriogenesis is indicated in Table 2.64
Studies in vitro and in vivo have taught us much
bout the importance of VEGF, FGF2, and other factors
n angiogenesis. However, the profound defects of
ice made deficient for the genes producing one or
nother of these factors provide very clear definitions
f the functions of these agents. For example, VEGF
eterozygous mice are embryonic lethal and have pro-
oundly impaired vasculogenesis.65 Conversely, mice
ompletely deficient in FGF2 have intact vasculogen-
sis but decreased tone in vascular smooth muscle.66,67
DGFB knockout mice lack microvascular pericytes,
nd develop capillary aneurysm, endothelial hyperpla-
ia, and hemorrhages.68
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368 V. Pires de Camargo et alOther sources of information on key genes in angio-
enesis include patients with familial syndromes involv-
ng vascular abnormalities. For example, hereditary
emorrhagic telangiectasia is characterized by arterio-
enous malformations without intervening capillaries,
hich are caused by defects in TGF- signaling from
utation or deletion of genes such as endoglin (ENG)
r activity receptor-like kinase 1 (ACVRL1 ALK1).69,70
avernous malformations of the central nervous system
lso occur in familial syndromes, and involve loss of
enes such as CCM1 or mutations in KRIT1. These
ndings can be recapitulated in mouse models, al-
hough the correspondence between the human gene
lteration and the mouse gene knockout model is not
erfect.
After a slow start in finding agents that block angio-
enesis that may be relevant for blocking tumor neo-
ngiogenesis, there is now a plethora of agents, both
onoclonal antibody bevacizumab and oral agents,
hat block signaling of angiogenic pathways in tumors
nd normal cells alike. One of the first of these was
umagillin analog TNP-470, which inhibits FGF2-medi-
ted endothelial cell proliferation, and showed some
ctivity in early clinical trials,71 but ultimately was not
pproved for human use.71
Phase I and II studies of thrombospondin mimetic
BT-510 have shown significant (6 month) disease sta-
ilization for 34% of patients on study.72 Notably, it also
as observed that low patient circulating endothelial
ell levels in the blood were associated with better
rognosis than patients with greater numbers of circu-
ating endothelial cells.
Adding bevacizumab to cytotoxic chemotherapy has
mproved survival in phase III studies in a variety of
pithelial cancers. The combination doxorubicin–bev-
cizumab was evaluated in a small phase II study of 17
valuable patients, most with leiomyosarcoma. Only
wo PRs were observed, which was not enough to
erit continuation of the study.73 Six patients devel-
ped cardiac G2 or worse toxicity on therapy. While
ome of the toxicity could be attributed to patients
eceiving up to 600 mg/m2 doxorubicin, four patients
eveloped toxicity with relatively modest cumulative
oses of doxorubicin, indicating possible negative ef-
ects of bevacizumab when given with other drugs
ausing potential cardiac toxicity. This small study can-
ot be considered an adequate evaluation of bevaci-
umab in patients with sarcoma. For example, a phase
I study of bevacizumab against angiosarcoma is under-
ay, but the results are not yet available.
Among the anti-angiogenic TK inhibitors, sunitinib,
azopanib, and sorafenib have all undergone initial
valuation in patients with sarcoma. Sunitinib yielded
nly PRs in patients with desmoplastic small round cell
umor and minor responses in metastatic hemangio-
ericytoma/solitary fibrous tumor and metastatic giant
ell tumor of bone.74 While case reports indicated ac- aivity in chordomas, there were no PRs according to
esponse Evaluation Criteria in Solid Tumors (RECIST)
een in seven patients treated on the study.74
Pazopanib, another inhibitor of VEGF receptors 1, 2,
nd 3, KIT, and PDGF receptors A and B, was examined
n a Simon two-stage design in four strata (leiomyosar-
oma, liposarcoma, synovial sarcoma, and other sarco-
as), with only the liposarcoma stratum not complet-
ng accrual due to low rate of PFS at 12 weeks.75
azopanib is now under study in phase III trials, includ-
ng one in patients with sarcoma.
Sorafenib was examined in a multicenter study in
47 patients on six different arms.76 The only activity
bserved occurred in 1/37 patients with leiomyosar-
oma with a response, and 5/37 angiosarcoma patients
ith a PR, one of which became a prolonged CR. It is
omewhat surprising that more activity was not ob-
erved in the angiosarcoma arm, since it is posited that
his, of all tumors, should be dependent on VEGF for
urvival. Minor responses were seen in patients with
alignant peripheral nerve sheath tumor and synovial
arcoma, although one patient with synovial sarcoma
xperienced life-threatening hemoptysis from lung me-
astases within 10 days of starting sorafenib. This pa-
ient developed a PR off protocol when put on a lower
ose of sorafenib. Reductions from the US Food and
rug Administration–approved dose of 400 mg oral
wice daily were necessary in 61% of patients due more
or skin toxicity than for other adverse events.
While anthracyclines and taxanes have well-recog-
ized activity against angiosarcoma,77–80 it also is worth
oting that sirolimus has activity against Kaposi sar-
oma,81 which itself is caused by infection with human
erpes virus 8 (Kaposi sarcoma herpes virus)82 either
lone or in concert with human immunodeficiency
irus, on the basis of a viral G-protein–coupled recep-
or that activates TSC2 and mTOR. This gives another
ine of therapy to consider in combination for patients
ho have different forms of vascular sarcomas apart
rom angiosarcoma.
Thus, there appears to be only modest activity of
nti-angiogenic therapy against sarcomas of soft tissue
nd bone; however, combinations of agents are just
ow being evaluated. Both translational and further
linical trials will better define this important series of
ignaling pathways in tumors and tumor vasculature in
he coming years.
UMMARY
The reports presented here indicate a new and ex-
iting phase for the development of molecularly tar-
eted therapeutics in sarcoma. GIST remains the flag-
hip, leading us past the initial excitement associated
ith proof that rationally designed therapeutic strate-
ies can have an impact in the clinic, so that we now
re forced to ask questions as to how to translate
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Other targetable sarcomas 369linical responses into cures. We are now seeing the
xtension of the GIST paradigm—target discovery fol-
owed by clinical intervention resulting in clinical ben-
fit—to other sarcoma types. These include the role of
SF1 in tenosynovial giant cell tumor, and hopefully
DM2 and CDK4 in well-differentiated and dedifferen-
iated liposarcoma. While target discovery has tradi-
ionally been based on genetic approaches, novel pro-
eomic tools will allow high-throughput identification
f pathways that may be targeted in sarcoma which do
ot carry the mutational “mark of the beast.” These
on-mutational targets present attractive options for
ur available armamentarium in diseases like chordoma
nd ASPS. In other cases, the target is a physiologic
rocess—angiogenesis—even where no direct muta-
ions exist to date. In particular, sarcomas arising in
elation to vasculature structures, like angiosarcoma,
ay be susceptible to anti-angiogenic strategies. Fi-
ally, in some cases, the clear sensitivity of some
arcomas to agents such as trabectedin suggests a
olecular specificity that remains to be elucidated.
he pace of progress is accelerating, and promises
uch as we move beyond GIST.
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